




RealRate

PHARMACEUTICAL 2019

Lipocine Inc
Rank 240 of 361

LIPOCINE®
ENHANCING HEALTH



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lipocine Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipocine Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Lipocine Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 57% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	20,809
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,492
Liabilities, Non-Current	6,927
Other Assets	24
Other Compr. Net Income	3.7
Other Expenses	0.70
Other Liabilities	0
Other Net Income	-334
Other Revenues	428
Property and Equipment	19
Research and Development	6,465
Selling, General and Administrative Expense	5,289

Output Variable	Value in 1000 USD
Assets	20,852
Liabilities	11,418
Expenses	11,755
Revenues	428
Stockholders Equity	9,434
Net Income	-11,660
Comprehensive Net Income	-11,658
BaseVar	22,395
ECR before Limited Liability	55%
Economic Capital Ratio	193%